In a mid-stage trial, Achillion's experimental drug, sovaprevir, demonstrated an excellent efficacy rate and safety profile.
Achillion hepatitis C drug shows promise in mid-stage study
Tue Aug 7, 2012 8:37pm EDT
(Reporting by Zeba Siddiqui in Bangalore; Editing by Anthony Kurian)
(Reuters) - Achillion Pharmaceuticals Inc said its experimental hepatitis C drug showed promising interim data in a mid-stage trial, sending its shares higher in extended trade.
The company said the drug sovaprevir, when given along with the standard therapy of pegylated interferon and ribavirin, showed no detectable virus level in a majority of patients four weeks after the end of the treatment period.
Of the 39 patients who received 12 weeks of additional standard therapy following 12 weeks of the combination therapy, a total of 33 patients in three different dosage arms showed sustained viral response a month later.
Hep C Trial with Sovaprevir Has 85% Success Rate
August 20, 2012
Achillion hepatitis C drug shows promise in mid-stage study
Tue Aug 7, 2012 8:37pm EDT
(Reporting by Zeba Siddiqui in Bangalore; Editing by Anthony Kurian)
(Reuters) - Achillion Pharmaceuticals Inc said its experimental hepatitis C drug showed promising interim data in a mid-stage trial, sending its shares higher in extended trade.
The company said the drug sovaprevir, when given along with the standard therapy of pegylated interferon and ribavirin, showed no detectable virus level in a majority of patients four weeks after the end of the treatment period.
Of the 39 patients who received 12 weeks of additional standard therapy following 12 weeks of the combination therapy, a total of 33 patients in three different dosage arms showed sustained viral response a month later.
Continue reading this entire article:
http://www.reuters.com/article/2012/08/08/us-achillon-hepatitisstudy-idUSBRE87700320120808